Treating autism through the gut? Axial Therapeutics refuels on its exploration of the gut-brain axis
If Stewart Campbell had said five years ago that you could treat conditions of the brain through the gut, you probably would have thought he was crazy — or at least that’s what he likes to say.
Since then, a crop of biotechs exploring the gut-brain axis has gotten the attention of some well-known investors. Campbell’s Axial Therapeutics is now the latest, unveiling a $37.25 million Series C round on Wednesday morning that brings the company’s total raise to just over $90 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.